Breast tumor treatment with anti-CXCR1 compositions
AssigneeThe Regents of the University of Michigan
InventorsMax S. Wicha, Christophe Ginestier
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).
Claims7
A method for reducing or eliminating breast cancer stem cells in a subject having a breast tumor comprising said stem cells, said method comprising:
- administering a compound to said subject under conditions such that cancer stem cells within said breast tumor are killed _and said breast tumor is treated, wherein said compound is an anti-CXCR1 antibody, Repertaxin, or a Repertaxin derivative.
A method for reducing or eliminating breast cancer stem cells during the development of metastasis from a breast tumor comprising said stem cells in a subject, said method comprising:
- administering a compound to said subject under conditions such that cancer stem cells within said breast tumor are killed and development of metastasis from said breast tumor is reduced, wherein said compound is Repertaxin, or a Repertaxin derivative.
Dependencies are inferred from the claim text.